Cipher Pharmaceuticals Reports Q3 GAAP EPS of C$0.43 and Revenue of C$12.7 Million
Cipher Pharmaceuticals has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) of C$0.43. Total revenue for the quarter reached C$12.7 million, representing a slight year-over-year decline of 1.0%. Adjusted EBITDA, which excludes non-recurring items related to an Arbitration Award, was reported at C$7.2 million, down 1% compared to the same period in the previous year. The company maintains a strong liquidity position with a cash balance of C$15.3 million and zero long-term debt as of September 30, 2026.